Head and Neck Cancer

PV QA 2 - Poster Viewing Q&A 2

MO_36_2491 - Relationship between Expression of ERCC1 and Effect of Cisplatin Concurrent Chemoradiation in Stage II-III Nasopharyngeal Carcinoma

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

Relationship between Expression of ERCC1 and Effect of Cisplatin Concurrent Chemoradiation in Stage II-III Nasopharyngeal Carcinoma
S. Chen1, H. Yang2, M. Wu3, X. Wei4, H. Ou5, M. Yi6, Y. Meng7, Z. Lin8, H. Huang1, and M. Yao9,10; 1Department of Medical Oncology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China, 2Department of Oncology, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China, 3Department of Oncology, the People’s Hospital of Shangrao, Shangrao, China, 4Tumor Molecular Laboratory, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China, 5Department of Pathology, The First Affiliated Hospital of Guangxi Traditional Chinese Medicine University, Nanning, Guangxi, China, 6Department of Pathology, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China, 7Department of Oncology, Baise People's Hospital, Baise, Guangxi, China, 8Department of Oncology, The Yulin First People's Hospital, Yulin, Guangxi, China, 9Case Western Reserve University, Cleveland, OH, 10University Hospitals, Cleveland Medical Center, Cleveland, OH

Purpose/Objective(s): To investigate the relationship between the expression of excision repair cross-complementing gene 1 (ERCC1) mRNA and protein and the effect of cisplatin concurrent chemoradiation (CCRT) in patients with stage II-IIIA nasopharyngeal carcinoma (NPC).

Materials/Methods: From June 2012 to June 2015, 78 patients with histologically diagnosed stage II-IIIA NPC (7th AJCC stage) were recruited. Immunohistoehemistry and RT-PCR methods were used to detect the expression of ERCC1 protein and mRNA in tumor tissues of these patients before CCRT and correlate with treatment outcomes. The primary endpoints included tumor response by RECIST 1.1 criteria and overall survival (OS). Survivals were calculated with Kaplan-Meier method. The differences between survivals were calculated by Log-rank test. The differences between groups were analyzed using the χ2 test. All statistical tests were two-side.

Results: Of 78 patients, 36 patients were positive in expression of ERCC1 protein (46.15%). The expression of ERCC1 protein was not associated with gender, age, T stage and N stage (p>0.05). There were 63 patients with complete response (CR), 7 with partial response (PR), 4 with stable disease (SD), and 4 with disease progression (PD). In 42 patients with negative ERCC1 expression, 41 had CR and PR (97.62%). In comparison, only 29/36 (80.56%) patients with positive ERCC1 protein achieved CR and PR (p=0.036). The expression of ERCC1 mRNA ranged from 0.456 to 1.412 (median 1.119), which was not associated with gender, age, T stage, and N stage (p>0.05). Patients with low ERCC1 mRNA expression (< median) had higher CR and PR (40/41 versus 30/37 for high expression, p=0.043). The 5-year OS for all patients was 91.03%. The 5-year OS for those with negative ERCC1 protein expression was 92.86% versus 88.98% for those with positive ERCC1 protein (p=0.831). The 5-year OS for those with low ERCC1 mRNA expression was 92.68% versus 89.19% for those with high ERCC1 mRNA expression (p=0.887).

Conclusion: The expression of ERCC1 protein and mRNA correlated with poorer response to concurrent cisplatin chemoradiation in stage II-IIIA NPC. They were not correlated with 5-year OS possible due to small patient sample size and excellent treatment outcomes of these patients.

Author Disclosure: S. Chen: None. M. Wu: None. X. Wei: None. H. Huang: None.

Send Email for Shaojun Chen


Assets

MO_36_2491 - Relationship between Expression of ERCC1 and Effect of Cisplatin Concurrent Chemoradiation in Stage II-III Nasopharyngeal Carcinoma



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Relationship between Expression of ERCC1 and Effect of Cisplatin Concurrent Chemoradiation in Stage II-III Nasopharyngeal Carcinoma